Childhood multiple sclerosis: a review
- PMID: 16807911
- PMCID: PMC7168360
- DOI: 10.1002/mrdd.20105
Childhood multiple sclerosis: a review
Abstract
Multiple sclerosis (MS) is an autoimmune demyelinating disorder of the central nervous system (CNS) that is increasingly recognized as a disease that affects children. Similar to adult-onset MS, children present with visual and sensory complaints, as well as weakness, spasticity, and ataxia. A lumbar puncture can be helpful in diagnosing MS when CSF immunoglobulins and oligoclonal bands are present. White matter demyelinating lesions on MRI are required for the diagnosis; however, children typically have fewer lesions than adults. Many criteria have been proposed to diagnose MS that have been applied to children, mostly above 10 years of age. The recent revisions to the McDonald criteria allow for earlier diagnosis, such as after a clinically isolated event. However, children are more likely than adults to have monosymptomatic illnesses. None of the approved disease-modifying therapies used in adult-onset MS have been approved for pediatrics; however, a few studies have verified their safety and tolerability in children. Although children and adults with MS have similar neurological symptoms, laboratory (cerebrospinal fluid) data, and neuroimaging findings, the clinical course, pathogenesis, and treatment of childhood onset MS require further investigation.
Similar articles
-
[May neuroimaging findings of a child with multiple sclerosis surprise us? Clinical and radiological observation].Przegl Lek. 2016;73(3):197-200. Przegl Lek. 2016. PMID: 27349055 Polish.
-
MRI features of pediatric multiple sclerosis.Neurology. 2007 Apr 17;68(16 Suppl 2):S46-53. doi: 10.1212/01.wnl.0000259406.09052.75. Neurology. 2007. PMID: 17438238
-
Multiple sclerosis in Israeli children: incidence, an clinical, cerebrospinal fluid and magnetic resonance imaging findings.Isr Med Assoc J. 2012 Apr;14(4):234-9. Isr Med Assoc J. 2012. PMID: 22675841
-
[Diagnosis of multiple sclerosis: A review of the 2017 revisions of the McDonald criteria].Ideggyogy Sz. 2018 Sep 30;71(9-10):321-329. doi: 10.18071/isz.71.0321. Ideggyogy Sz. 2018. PMID: 30335264 Review. Hungarian.
-
Childhood autoimmune neurologic diseases of the central nervous system.Neurol Clin. 2003 Nov;21(4):745-64. doi: 10.1016/s0733-8619(03)00007-0. Neurol Clin. 2003. PMID: 14743647 Review.
Cited by
-
Management of multiple sclerosis in adolescents - current treatment options and related adherence issues.Adolesc Health Med Ther. 2010 Jun 17;1:31-43. doi: 10.2147/AHMT.S7594. eCollection 2010. Adolesc Health Med Ther. 2010. PMID: 24600259 Free PMC article. Review.
-
Promising candidate cerebrospinal fluid biomarkers of seizure disorder, infection, inflammation, tumor, and traumatic brain injury in pediatric patients.Clin Exp Pediatr. 2022 Feb;65(2):56-64. doi: 10.3345/cep.2021.00241. Epub 2021 Aug 23. Clin Exp Pediatr. 2022. PMID: 34425669 Free PMC article.
References
-
- Azoulay D, Vachapova V, Shihman B, et al. 2005. Lower brain‐derived neurotrophic factor in serum of relapsing remitting MS: Reversal by glatiramer acetate. J Neuroimmunol 167: 215–218. - PubMed
-
- Banwell B, Reder AT, Krupp L, et al. 2006. Safety and tolerability of interferon β‐1b in pediatric multiple sclerosis. Neurology 66: 472–476. - PubMed
-
- Barkhof F, Filippi M, Miller DH, et al. 1997. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120: 2059–2069. - PubMed
-
- Barkhof F, Hommes O, Scheltens P, et al. 1991. Quantitative MRI changes in gadolinium‐DTPA enhancement after high‐dose intravenous methylprednisolone in multiple sclerosis. Neurology 41: 1219–1222. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical